Cullinan Associates Inc. Decreases Position in Danaher Corporation $DHR

Cullinan Associates Inc. lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 7.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,200 shares of the conglomerate’s stock after selling 100 shares during the period. Cullinan Associates Inc.’s holdings in Danaher were worth $237,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. NBC Securities Inc. purchased a new stake in shares of Danaher during the 1st quarter valued at $176,000. Vest Financial LLC increased its position in shares of Danaher by 73.6% in the 1st quarter. Vest Financial LLC now owns 5,361 shares of the conglomerate’s stock valued at $1,099,000 after acquiring an additional 2,273 shares during the period. Sivia Capital Partners LLC increased its position in shares of Danaher by 34.0% in the 1st quarter. Sivia Capital Partners LLC now owns 1,890 shares of the conglomerate’s stock valued at $387,000 after acquiring an additional 480 shares during the period. Patriot Financial Group Insurance Agency LLC increased its position in shares of Danaher by 7.2% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 1,067 shares of the conglomerate’s stock valued at $219,000 after acquiring an additional 72 shares during the period. Finally, Kennebec Savings Bank increased its position in shares of Danaher by 3.8% in the 1st quarter. Kennebec Savings Bank now owns 3,052 shares of the conglomerate’s stock valued at $626,000 after acquiring an additional 111 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is owned by company insiders.

Danaher Price Performance

Shares of DHR opened at $215.05 on Monday. The business’s 50-day moving average is $200.19 and its two-hundred day moving average is $197.24. The company has a market capitalization of $153.98 billion, a P/E ratio of 45.75, a P/E/G ratio of 3.06 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the firm earned $1.72 EPS. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 27.23%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DHR shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research report on Saturday, September 27th. Guggenheim reissued a “buy” rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Finally, Barclays reissued an “overweight” rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.